Legis Daily

To amend the Public Health Service Act to require reporting by drug manufacturers to increase transparency in drug pricing, and for other purposes.

USA115th CongressHR-4116| House 
| Updated: 10/27/2017
Lloyd Doggett

Lloyd Doggett

Democratic Representative

Texas

Cosponsors (33)
Marcy Kaptur (Democratic)Raúl M. Grijalva (Democratic)Mark Pocan (Democratic)Karen Bass (Democratic)David N. Cicilline (Democratic)Emanuel Cleaver (Democratic)Brian Higgins (Democratic)Carol Shea-Porter (Democratic)Steve Cohen (Democratic)Rosa L. DeLauro (Democratic)Vicente Gonzalez (Democratic)Ro Khanna (Democratic)Henry C. "Hank" Johnson (Democratic)Al Green (Democratic)Mark DeSaulnier (Democratic)Keith Ellison (Democratic)John Conyers (Democratic)Jerrold Nadler (Democratic)Mark Takano (Democratic)Luis V. Gutierrez (Democratic)Pramila Jayapal (Democratic)Eleanor Holmes Norton (Democratic)Jamie Raskin (Democratic)Elijah E. Cummings (Democratic)Maxine Waters (Democratic)Nydia M. Velázquez (Democratic)Peter Welch (Democratic)Bennie G. Thompson (Democratic)Earl Blumenauer (Democratic)Gwen Moore (Democratic)Chellie Pingree (Democratic)Grace F. Napolitano (Democratic)Judy Chu (Democratic)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Transparent Drug Pricing Act of 2017 This bill requires drug manufacturers to report specified financial and sales information, including drug pricing, tax credit, and patent information; violations are subject to civil penalties.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Oct 25, 2017
Introduced in House
Oct 25, 2017
Referred to the House Committee on Energy and Commerce.
Oct 27, 2017
Referred to the Subcommittee on Health.
  • October 25, 2017
    Introduced in House
  • October 25, 2017
    Referred to the House Committee on Energy and Commerce.
  • October 27, 2017
    Referred to the Subcommittee on Health.

Health

Accounting and auditingBusiness recordsCongressional oversightCorporate finance and managementGovernment studies and investigationsHealth care costs and insuranceInflation and pricesIntellectual propertyMarketing and advertisingMedical researchPrescription drugsProduct development and innovationResearch administration and fundingResearch and developmentSmall businessWages and earnings

To amend the Public Health Service Act to require reporting by drug manufacturers to increase transparency in drug pricing, and for other purposes.

USA115th CongressHR-4116| House 
| Updated: 10/27/2017
Transparent Drug Pricing Act of 2017 This bill requires drug manufacturers to report specified financial and sales information, including drug pricing, tax credit, and patent information; violations are subject to civil penalties.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Oct 25, 2017
Introduced in House
Oct 25, 2017
Referred to the House Committee on Energy and Commerce.
Oct 27, 2017
Referred to the Subcommittee on Health.
  • October 25, 2017
    Introduced in House
  • October 25, 2017
    Referred to the House Committee on Energy and Commerce.
  • October 27, 2017
    Referred to the Subcommittee on Health.
Lloyd Doggett

Lloyd Doggett

Democratic Representative

Texas

Cosponsors (33)
Marcy Kaptur (Democratic)Raúl M. Grijalva (Democratic)Mark Pocan (Democratic)Karen Bass (Democratic)David N. Cicilline (Democratic)Emanuel Cleaver (Democratic)Brian Higgins (Democratic)Carol Shea-Porter (Democratic)Steve Cohen (Democratic)Rosa L. DeLauro (Democratic)Vicente Gonzalez (Democratic)Ro Khanna (Democratic)Henry C. "Hank" Johnson (Democratic)Al Green (Democratic)Mark DeSaulnier (Democratic)Keith Ellison (Democratic)John Conyers (Democratic)Jerrold Nadler (Democratic)Mark Takano (Democratic)Luis V. Gutierrez (Democratic)Pramila Jayapal (Democratic)Eleanor Holmes Norton (Democratic)Jamie Raskin (Democratic)Elijah E. Cummings (Democratic)Maxine Waters (Democratic)Nydia M. Velázquez (Democratic)Peter Welch (Democratic)Bennie G. Thompson (Democratic)Earl Blumenauer (Democratic)Gwen Moore (Democratic)Chellie Pingree (Democratic)Grace F. Napolitano (Democratic)Judy Chu (Democratic)

Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Accounting and auditingBusiness recordsCongressional oversightCorporate finance and managementGovernment studies and investigationsHealth care costs and insuranceInflation and pricesIntellectual propertyMarketing and advertisingMedical researchPrescription drugsProduct development and innovationResearch administration and fundingResearch and developmentSmall businessWages and earnings